| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5698582 | SANOFI AVENTIS US | Compositions containing taxane derivatives |
Jul, 2012
(11 years ago) | |
| US5714512 | SANOFI AVENTIS US | Compositions containing taxane derivatives |
Jul, 2012
(11 years ago) | |
| US5750561 | SANOFI AVENTIS US | Compositions containing taxane derivatives |
Jul, 2012
(11 years ago) | |
|
US5698582 (Pediatric) | SANOFI AVENTIS US | Compositions containing taxane derivatives |
Jan, 2013
(11 years ago) | |
|
US5714512 (Pediatric) | SANOFI AVENTIS US | Compositions containing taxane derivatives |
Jan, 2013
(11 years ago) | |
|
US5750561 (Pediatric) | SANOFI AVENTIS US | Compositions containing taxane derivatives |
Jan, 2013
(11 years ago) | |
| US5438072 | SANOFI AVENTIS US | Taxoid-based compositions |
Nov, 2013
(10 years ago) | |
|
US5438072 (Pediatric) | SANOFI AVENTIS US | Taxoid-based compositions |
May, 2014
(9 years ago) | |
Taxotere is owned by Sanofi Aventis Us.
Taxotere contains Docetaxel.
Taxotere has a total of 8 drug patents out of which 8 drug patents have expired.
Expired drug patents of Taxotere are:
- US5698582
- US5714512
- US5750561
- US5698582*PED
- US5714512*PED
- US5750561*PED
- US5438072
- US5438072*PED
Taxotere was authorised for market use on 03 August, 2010.
Taxotere is available in injectable;injection dosage forms.
The generics of Taxotere are possible to be released after 22 May, 2014.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Nov 13, 2013 |
| M(M-61) | May 13, 2013 |
Drugs and Companies using DOCETAXEL ingredient
Market Authorisation Date: 03 August, 2010
Treatment: NA
Dosage: INJECTABLE;INJECTION
How can I launch a generic of TAXOTERE before it's drug patent expiration?
More Information on Dosage
TAXOTERE family patents
